<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455090</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-014</org_study_id>
    <secondary_id>2011-002788-11</secondary_id>
    <nct_id>NCT01455090</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications</brief_title>
  <official_title>Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the rate of sustained virologic response (SVR)
      SVR12, where SVR12 is defined as HCV RNA &lt; LOQ (detectable or undetectable) 12 weeks
      post-treatment in Genotype 1 &amp; Genotype 4 treatment naive patients, and Genotype (GT1)
      infected patients who are prior null responders to pegIFN/ribavirin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IND numbers: 79,599; 101,943
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2011</start_date>
  <completion_date type="Actual">July 31, 2015</completion_date>
  <primary_completion_date type="Actual">March 31, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response (SVR) at 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HCV ribonucleic acid (RNA) &lt; limit of quantification (LOQ) (detectable and undetectable)</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HCV ribonucleic acid (RNA) undetectable</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who experience viral breakthrough</measure>
    <time_frame>Formal analysis at SVR12, Week 48 of follow up period (or upon occurrence)</time_frame>
    <description>viral breakthrough defined as:
Any increase in HCV RNA ≥ 1 log10 from nadir or
Any quantifiable HCV RNA ≥ 25 IU/mL (&gt; LOQ) on or after Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who experience viral relapse defined as confirmed quantifiable HCV RNA ≥ 25 IU/mL (&gt;LOQ) in a subject with HCV RNA &lt; LOQ or undetectable at End of treatment (EOT)</measure>
    <time_frame>End of treatment (Maximum up to 24 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 12 hours (C12) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 24 hours (C24) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV genomic substitutions associated with exposure of BMS-650032, BMS-790052, and BMS-791325</measure>
    <time_frame>At the time of viral breakthrough or relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of deaths, serious adverse events (SAEs), discontinuations due to adverse events (AEs), severity Grade 3/4 AEs, and severity Grade 3/4 laboratory abnormalities</measure>
    <time_frame>Formal analysis at week 48 of follow up period (or upon occurrence)</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
BMS-790052 60 mg tablet by mouth once daily for 24 Weeks
BMS 791325 75 mg table by mouth twice daily for 24 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 60 mg tablet by mouth once daily for 12 Weeks
BMS 791325 75 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2
BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
BMS-790052 60 mg tablet by mouth once daily for 24 Weeks
BMS 791325 150 mg table by mouth twice daily for 24 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 60 mg tablet by mouth once daily for 12 Weeks
BMS 791325 150 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-naive subjects
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
BMS 791325 75 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-naive subjects
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
BMS 791325 150 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 4 treatment-naive subjects
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
BMS 791325 75 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 4 treatment-naive subjects
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
BMS 791325 150 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-null/non-responder subjects
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
BMS 791325 75 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-null/non-responder subjects
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
BMS 791325 150 mg table by mouth twice daily for 12 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-null/non-responder subjects
BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks
BMS 791325 75 mg table by mouth twice daily for 24 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-null/non-responder subjects
BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks
BMS 791325 150 mg table by mouth twice daily for 24 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Genotype 1 treatment-naive subjects
BMS-650032 200 mg tablets orally twice daily 12 weeks
BMS-790052 30 mg tablets orally twice daily 12 weeks
BMS-791325 75 mg tablets orally twice daily 12 weeks
Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is &lt; 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032</intervention_name>
    <arm_group_label>Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV</arm_group_label>
    <other_name>Asunaprevir (ASV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-790052</intervention_name>
    <arm_group_label>Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV</arm_group_label>
    <other_name>Daclatasvir (DCV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)</arm_group_label>
    <arm_group_label>Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)</arm_group_label>
    <arm_group_label>Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV</arm_group_label>
    <other_name>Copegus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages ≥18 years of age

          -  Subjects who are naive to HCV treatment, defined as no previous exposure to an
             Interferon (IFN), Ribavirin (RBV); or any HCV-specific direct acting antiviral or
             experimental therapy or subjects who are null responders to previous pegylated
             Interferon alfa (pegIFNα) plus Ribavirin (RBV) treatment

          -  Subjects should have chronic hepatitis C (CHC) as documented by:

               1. Positive for anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least
                  6 months prior to screening, and positive for HCV RNA and Anti-HCV antibody at
                  the time of screening, or

               2. Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver
                  biopsy consistent with chronic HCV infection (or a liver biopsy performed prior
                  to enrollment with evidence of CHC disease, such as the presence of fibrosis)

          -  HCV genotype 1a, 1b or 4 only

          -  HCV RNA viral load of ≥10,000 IU/mL at screening

          -  Have one of the following:

               1. Documented Fibrotest score of ≤0.72 and aspartate transferase (transminase) to
                  platelet ratio index (APRI) ≤2; OR

               2. Documented liver biopsy within 36 months preceding Day 1 showing absence of
                  cirrhosis OR

               3. Documented Fibroscan® ultrasound (where approved) within 12 months of screening
                  showing absence of cirrhosis

          -  Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive

          -  Subjects with compensated Child-Pugh A cirrhosis as documented by history of cirrhosis
             with any prior liver biopsy or Fibroscan® ultrasound (where approved) within 12 months
             prior to screening

        Exclusion Criteria:

          -  Evidence of a medical condition associated with chronic liver disease other than HCV
             (such as but not limited to: hemochromatosis, autoimmune hepatitis,metabolic liver
             disease, alcoholic liver disease, toxin exposures)

          -  History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
             with diuretics or paracentesis

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to enrollment

          -  Documented or suspected hepatocellular carcinoma (HCC)

          -  Positive for hepatitis B surface antigen (HBsAg)

          -  Positive for Human Immunodeficiency Virus-1 (HIV-1) and/or Human Immunodeficiency
             Virus-2 (HIV-2) antibodies

          -  Alanine transferase (transminase) (ALT) &gt;5x upper limit of normal (ULN)

          -  Total Bilirubin ≥2 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter J Ruane Md Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Va Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research And Education, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute, Llc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Denver And Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates, Llc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Id Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Care Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James J Peters Vamc</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Specialists Of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clichy Cedex</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>9410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 08</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion De Investigacion De Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 9, 2015</disposition_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

